About

Deepika Reddy is a professor specializing in Endocrinology & Metabolism at the University of Utah. She is board certified by the American Board of Internal Medicine in Endocrinology, Diabetes & Metabolism. Her clinical practice is primarily based at the Utah Diabetes & Endocrinology Center in Salt Lake City, where she provides expert care for patients with endocrine and metabolic disorders. Dr. Reddy is highly regarded by her patients for her knowledge, caring manner, and patient-centered approach, often taking the time to listen, explain, and collaborate on personalized treatment plans. She is recognized for her thoroughness, professionalism, and ability to communicate complex medical information in an understandable way. Her dedication to patient care and her expertise in endocrinology make her a leading figure in her field at the university.

Research topics

• Internal medicine
• Medicine
• Sociology
• Political Science
• Pediatrics
• Obstetrics
• Surgery
• Audiology
• Demography
• Environmental health

Selected publications

• Documentation of social determinants of health for patients with type 2 diabetes in Epic Cosmos

  JAMIA Open · 2025-08-08 · 3 citations

  articleOpen access

  Objectives: Type 2 diabetes (T2D) is a growing public health burden with persistent racial and ethnic disparities. . This study assessed the completeness of social determinants of health (SdoH) data for patients with T2D in Epic Cosmos, a nationwide, cross-institutional electronic health recors (EHR) database. Materials and Methods: The study included adults with T2D (ICD-10: E11.*) with encounters between 2022 and 2024. We analyzed 11 individual-level SDoH data elements across 5 domains-financial strain, food insecurity, housing instability, intimate partner violence, and transportation needs-and 4 components of the Social Vulnerability Index (SVI), representing neighborhood-level SDoH. Data completeness for each data element (ie, the proportion of individuals with non-missing values) was evaluated using generalized linear models, adjusting for source healthcare organization, sex, and age. Results: Among 12 031 927 individuals with T2D, adjusted completeness for individual-level SDoH data elements ranged from 11.2% to 31.5%, varying by data element and racial/ethnic group. American Indian or Alaska Native, Asian, Hispanic, and Native Hawaiian or Other Pacific Islander individuals had lower completeness for all individual-level SDoH compared to White individuals. In contrast, SVI data elements were available for nearly all patients since they are derived from patient addresses routinely collected in EHRs. Discussion: While SVI data elements were widely available, individual-level SDoH data elements had significant missingness, limiting their usability for secondary analyses. Racial/ethnic disparities in SDoH completeness further complicate their use. Conclusion: Standardized, equitable SDoH collection is critical to close documentation gaps, reduce disparities, and enable accurate, bias-resistant analyses in T2D care.

  PublisherOA PDFDOI

• Patient and provider factors associated with follow-up for positive depression screens in adults: a retrospective review of University of Utah primary and specialty care clinics

  BMJ Open · 2025-01-01

  reviewOpen accessSenior author

  OBJECTIVE: To identify patient and provider factors associated with lower rates of follow-up for positive depression screens in outpatient settings. DESIGN: Retrospective cohort study with electronic health record analysis investigating factors associated with follow-up care for patients with moderate-to-severe depressive symptoms. Patient and provider variables were associated with rates of follow-up for positive depression screens. SETTING: University of Utah and University of Utah Health-affiliated primary care and specialty clinics. PARTICIPANTS: Adults who screened positive for depressive symptoms (score≥10) on the Patient Health Questionnaire (PHQ-9) at an ambulatory visit between 1 January 2021 and 31 January 2022. A total of 17 651 patients were included in the study. OUTCOME MEASURES: Follow-up for positive depression screens was defined as a new antidepressant prescription or completed mental health visit. Variables associated with follow-up included patient demographic data, anthropometric measures, geographical classification, primary language, comorbidities and socioeconomic factors as well as provider demographics, level of training and clinic type. RESULTS: 5396 patients (30.6%) did not receive follow-up care for a positive PHQ-9 screen. Factors associated with lower rates of follow-up included male patients (gender; p=0.013), older patients (age group; p=0.016), non-White patients (ethnicity; p<0.0001), non-English (primary language; p<0.0001), lack of insurance (p<0.0001), older providers (p=0.027), male providers (p=0.0037) and attending-level providers (p<0.0001). CONCLUSIONS: Significant discrepancies in follow-up for positive depression screens in the ambulatory setting exist, particularly among racial/ethnic minority groups and patients who are non-native English speakers. Older providers and attending-level providers were less likely to facilitate follow-up for positive depression screens in their clinics.

  PublisherOA PDFDOI

• Characterization and Racial Stratification of Social Determinants of Health for Individuals with Type 2 Diabetes as Recorded in Electronic Health Records: Implications for Artificial Intelligence Development

  medRxiv · 2024-10-08 · 1 citations

  preprintOpen access

  Abstract Background Accurate documentation of social determinants of health (SDoH) in electronic health records (EHRs) is critical for developing equitable AI models for diabetes management. This study investigates SDoH data in a cross-institutional EHR database. Methods We analyzed neighborhood-level (i.e., social vulnerability index [SVI], Rural-Urban Community Area [RUCA]) and individual-level SDoH (e.g., preferred language, marital status, tobacco, alcohol, and substance use) within the Epic Cosmos database, focusing on adults diagnosed with T2D (E11.*) who had encounters between 2021 and 2023. We measured data completeness (i.e., the proportion of individuals who have a non-missing value) and the prevalence of non-canonical values (e.g., preference for language other than English) for each available SDoH variable. Findings The study included 12,696,680 individuals with T2D. SVI, RUCA and preferred language were available for all individuals, while marital status, and smoking data were available for over 90%. However, financial needs, interpersonal violence, social activity, and physical activity were present in EHRs for 7.6%-24.6% of the population depending on race/ethnicity. Minority groups experienced lower data completeness and higher burden of non-canonical values compared to White individuals. Interpretation Neighborhood-level and some individual-level SDoH have potential for use in AI development and evaluation. Other SDoH data cannot be used without additional analysis to address high amounts of missing data. Significant disparities in completeness exist across racial/ethnic groups. Addressing these data gaps may require government and payer mandates, standardized SDoH screening tools, and personnel training. Highlights This study examined social determinants of health (SDoH) data for adults with type 2 diabetes in a cross-institutional electronic health record (EHR) database to support equitable AI model development. Neighborhood-level SDoH data and some individual-level SDoH data (individual-level SDoH (i.e., race/ethnicity, preferred language, marital status) were highly complete. Disparities in SDoH data completeness by race/ethnicity underscore the need for standardized SDoH documentation.

  PublisherOA PDFDOI

• Prevalence and determinants of sleep disturbances among pregnant women: an Indian community-based cross-sectional study

  Sleep and Biological Rhythms · 2024-11-13 · 4 citations

  articleOpen accessSenior author
  PublisherOA PDFDOI

• Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis

  medRxiv (Cold Spring Harbor Laboratory) · 2024 · 5 citations

  • Political Science
  • Sociology
  • Medicine

  Background: Type 2 diabetes (T2D) represents a major public health burden in the United States, with racial disparities in medication use potentially exacerbating inequities in health outcomes. This study examined racial/ethnic differences in the prescription of high-efficacy glucose-lowering medications for T2D using a large EHR network (TriNetX). Methods: A retrospective cohort study included adults with uncomplicated T2D (ICD-10: E11.9), categorized as Hispanic or Latino (Hispanic) or non-Hispanic American Indian/Alaska Native (AI/AN), Asian, Black, Native Hawaiian/Pacific Islander (NH/PI), and White. Adjusted odds ratios for GLP-1 receptor agonist medications (tirzepatide, semaglutide, and dulaglutide) prescriptions in 2022-2023 were calculated by race/ethnicity, controlling for age, sex, and Charlson Comorbidity Index. Findings: Among 57,320 patients included in the analysis, we observed significant racial disparities in the prescribing of GLP-1 medications. Compared to White patients, for tirzepatide, adjusted odds ratios prescriptions were 0.6 (95% CI: 0.4-0.9) for AI/AN, 0.3 (95% CI: 0.3-0.4) for Asian, 0.7 (95% CI: 0.6-0.9) for Black, 0.4 (95% CI: 0.3-0.5) for Hispanic, and 0.4 (95% CI: 0.3-0.6) for NH/PI. For semaglutide, adjusted odds ratios were 0.8 (95% CI: 0.7-0.9) for AI/AN, 0.5 (95% CI: 0.5-0.6) for Asian, 0.8 (95% CI: 0.7-0.9) for Black, 0.6 (95% CI: 0.6-0.7) for Hispanic, and 0.6 (95% CI: 0.5-0.8) for NH/PI. For dulaglutide, adjusted odds ratios were 1.2 (95% CI: 1.0-1.4) for AI/AN, 0.5 (95% CI: 0.4-0.5) for Asian, 1.0 (95% CI: 0.9-1.1) for Black, 0.9 (95% CI: 0.8-1.0) for Hispanic, and 0.5 (95% CI: 0.4-0.6) for NH/PI. Interpretation: Racial disparities in high-efficacy diabetes medication prescriptions may contribute to unequal health outcomes in T2D, highlighting the need for targeted research and interventions for equitable diabetes care.

  PublisherOA PDFDOI

• Effect of Drill Induced Noise on Contralateral Normal Ear Following Cortical Mastoidectomy

  Indian Journal of Otolaryngology and Head & Neck Surgery · 2023-08-10

  articleOpen access1st authorCorresponding
  PublisherOA PDFDOI

• Abstract #1185203: Regular blood pressure screening to decrease stroke risk in Hypertension and Brachydactyly syndrome

  Endocrine Practice · 2022-05-01

  article1st authorCorresponding
  PublisherDOI

• Ototoxicity and Teprotumumab

  Annals of Otology Rhinology & Laryngology · 2021 · 29 citations

  • Medicine
  • Audiology
  • Internal medicine

  OBJECTIVES: Teprotumumab, a novel monoclonal antibody, targets the insulin-like growth factor 1 (IGF-1) receptor. IGF-1 receptors, found in muscle and fat adjacent to the eye and implicated in Graves Ophthalmopathy, are also in the cochlea. In clinical trials, 5 participants reported self-limited audiologic symptoms but there are no objective data in the literature. The aim of this report is to describe one of the first known cases of teprotumumab-induced irreversible sensorineural hearing loss. METHODS: Case report at a tertiary referral center. RESULTS: A 61 year old female with Graves ophthalmopathy presented with bilateral hearing loss, sound distortion, and tinnitus following treatment with teprotumumab. Audiogram showed mild sloping to moderately-severe sensorineural hearing loss. Repeat audiometry obtained 4 months after cessation of teprotumumab and treatment with oral corticosteroids was unchanged. CONCLUSIONS: This is one of the first descriptive cases of ototoxicity resulting in irreversible sensorineural hearing loss in the setting of treatment with teprotumumab. Periodic audiologic evaluations should be recommended to patients on teprotumumab.

  PublisherDOI

• Interpregnancy Body Mass Index Change and Offspring Mortality Risk following the Second Pregnancy

  American Journal of Perinatology · 2021 · 4 citations

  Senior authorCorresponding
  • Medicine
  • Obstetrics
  • Pediatrics

  OBJECTIVE: The aim of the study is to examine the impact of maternal interpregnancy body mass index (BMI) change on subsequent offspring mortality risk. STUDY DESIGN: . Our primary outcome was all-cause age-specific mortality during four time periods: neonatal (≤28 days), infant (29 days to <1 year old), childhood ((≥1 to <5 years old), and late childhood (5 to <18 years old). We also examined mortality specifically attributed to congenital anomalies. Analyses used Cox proportional hazard models stratified by full term (≥37 weeks) and preterm (<37 weeks) deliveries. All models were adjusted for relevant confounders. RESULTS: also had increased risk of mortality associated with congenital anomalies or conditions arising during the neonatal period following their subsequent delivery. CONCLUSION: Women with significant interpregnancy weight gain and modest weight loss have a significant increased risk of neonatal mortality following their subsequent pregnancy. KEY POINTS: · Significant weight gain between deliveries increases the risk of neonatal death.. · Modest weight loss between deliveries increases the risk of neonatal death.. · This risk may be partially explained by increased risk of congenital malformations..

  PublisherOA PDFDOI

• 724: Interpregnancy BMI changes and offspring mortality following second pregnancy

  American Journal of Obstetrics and Gynecology · 2018-01-01 · 1 citations

  articleOpen accessSenior author
  PublisherOA PDFDOI

Frequent coauthors

• Zhe Yu

  Nanjing Agricultural University

  3 shared

• Marcela C. Smid

  3 shared

• D. Ware Branch

  University of Utah

  3 shared

• Ken R. Smith

  3 shared

• Huong Meeks

  University of Utah

  3 shared

• Alison Fraser

  University of Utah

  3 shared

• Jennifer West

  University of Queensland

  3 shared

• Matthew J. O’Brien

  Northwestern University

  2 shared